These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. The prevalence of tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders. de Jesus Mari J, Lima MS, Costa AN, Alexandrino N, Rodrigues-Filho S, de Oliveira IR, Tollefson GD. Eur Arch Psychiatry Clin Neurosci; 2004 Dec; 254(6):356-61. PubMed ID: 15538607 [Abstract] [Full Text] [Related]
12. Treatment of tardive dyskinesia. I. Clinical efficacy of a dopamine-depleting agent, tetrabenazine. Kazamatsuri H, Chien C, Cole JO. Arch Gen Psychiatry; 1972 Jul; 27(1):95-9. PubMed ID: 4555831 [No Abstract] [Full Text] [Related]
13. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Jankovic J, Beach J. Neurology; 1997 Feb; 48(2):358-62. PubMed ID: 9040721 [Abstract] [Full Text] [Related]
14. An ergot alkaloid preparation (Hydergine) versus papaverine in treating common complaints of the aged: double-blind study. Bazo AJ. J Am Geriatr Soc; 1973 Feb; 21(2):63-71. PubMed ID: 4631704 [No Abstract] [Full Text] [Related]
15. Tetrabenazine and movement disorders. Asher SW, Aminoff MJ. Neurology; 1981 Aug; 31(8):1051-4. PubMed ID: 6455607 [Abstract] [Full Text] [Related]